Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Heart Failure Devices: Raising Roadblocks To Readmission

Executive Summary

A new Medicare cost-control program aimed at reducing costly hospital readmissions has heart failure squarely in the cross-hairs, and the consequences could mean hundreds of thousands of dollars in lost Medicare revenue for hospitals that fail to meet the new readmission standards. As a result, providers are scrambling to implement programs to assess and reduce heart failure readmissions, and a growing number of device companies are touting a variety of technologies they believe could help them achieve that goal.

You may also be interested in...



Heart Failure: Next-Gen VADs Fuel Optimism Amid Challenges

Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.

ESC 2014 Shines Spotlight On The Future Of Cardiology

The cardiology sector, long known as one of the most innovative in medtech, has a new wave of technologies on the horizon that could help reinvigorate the sector and create new multibillion-dollar market opportunities for device manufacturers. We take a closer look at these technologies, which include vagal nerve stimulation, remote monitoring for heart failure, as well as innovation in the percutaneous coronary intervention space, all of which were all in the spotlight at the recent European Society of Cardiology Congress 2014 in Barcelona.

Digital Health Pushing Telemedicine To Center Stage

Remote monitoring is proving to be the driving force in the industry’s quest to reduce costs by keeping patients out of hospitals, and telemedicine is positioned to become a major part of that scheme. However, telemedicine has a number of components and players, and while the market offers opportunities, it could also prove to be somewhat disruptive to companies and products that do not fit in the envisioned landscape.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel